Dendreon Reimbursement Support:

We’ve got you covered

  • Dendreon now offers PROvide, a commercial co-pay program specific to patients with coverage from a private commercial health plan
  • PROvide supports eligible patients by covering any combination of
    cost—co-pays, co-insurance, or deductible costs—to a maximum of $6000
    over the 3 PROVENGE treatments

Dendreon ON Call is Now ONline!

  • Available 24/7 online, Dendreon ON Call offers a quick and convenient way to enroll patients, receive and monitor benefit verification information, view patient status and case history, send secure messages, and more.

Dendreon Reimbursement Support:

We've got you covered

  • All Medicare Administrative Contractor regions cover PROVENGE based on the FDA-approved label
  • Plans representing approximately 99% of patients with private insurance cover PROVENGE based on the FDA-approved label

NCD and Q-Code

In 2011, CMS1 issued a National Coverage Determination (NCD) and Q-code for PROVENGE that simplify patient coverage criteria and expedite electronic billing and payment.

All Medicare Administrative Contractors cover PROVENGE, and reimburse for administration2, based on the FDA-approved label, per the NCD.

Download the latest guide for updated coding and billing instructions, with annotated forms to help minimize errors that can delay reimbursement:

Start PROVENGE Therapy

To start PROVENGE—and access patient assistance and scheduling resources—enroll your patients through Dendreon ON Call.

Patient Assistance

Good News: 75% of patients receiving PROVENGE are expected to have minimal to $0 out of pocket costs. But for those with no coverage for PROVENGE, or who need help covering costs, Dendreon supports several patient assistance options, including:

 

1 Centers for Medicare and Medicaid Services
2 Administration reimbursement is retroactive for dates of service on or after June 30, 2011

INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.

Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

Full Prescribing Information